Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease

OBJECTIVE: To test the safety, tolerability, and pharmacokinetics of the anti- TNF-α monoclonal antibody, infliximab, in subjects with intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD). STUDY DESIGN: We conducted a multicenter, randomized, prospective trial of second IVIG infusion (2...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Burns, Jane C., Best, Brookie M., Mejias, Asuncion, Mahony, Lynn, Fixler, David E., Jafri, Hasan S., Melish, Marian E., Jackson, Mary Anne, Asmar, Basim I., Lang, David J., Connor, James D., Capparelli, Edmund V., Keen, Monica L., Mamun, Khalid, Keenan, Gregory F., Ramilo, Octavio
Format: Artigo
Langue:Inglês
Publié: 2008
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2856847/
https://ncbi.nlm.nih.gov/pubmed/18672254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jpeds.2008.06.011
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires